Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
前收盤價
US$19.07
−US$0.16 · -0.83%
盤中時間採用ET。市場資料可能有所延遲。
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
日內區間
目前US$19.07
52週區間
目前US$19.07
營業利益
淨利
| 項目(USD) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | — | — | 457.5萬 USD |
| 毛利 | — | — | — | — | −457.5萬 USD |
| 研究與開發 | 2.21億 USD | 1.89億 USD | 1.75億 USD | 1.27億 USD | 8064.5萬 USD |
| 銷售、一般及管理費用 | 9873.5萬 USD | — | — | — | 3626.4萬 USD |
| 營業費用 | 3.2億 USD | 2.62億 USD | 2.35億 USD | 1.77億 USD | 1.17億 USD |
| 利息收入 | 1362.5萬 USD | 2112萬 USD | 2335.6萬 USD | 1000.6萬 USD | 39萬 USD |
| 利息支出 | 885.9萬 USD | 789.3萬 USD | 666萬 USD | 416萬 USD | 222.3萬 USD |
| 折舊和攤銷 | 333.2萬 USD | 350.2萬 USD | 265.5萬 USD | 244.7萬 USD | 214.7萬 USD |
| 營業利益 | −3.2億 USD | −2.62億 USD | −2.35億 USD | −1.77億 USD | −1.21億 USD |
| 淨利 | −3.14億 USD | −2.47億 USD | −2.16億 USD | −1.74億 USD | −1.18億 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$24.75
上漲空間 29.79%報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI4903.96萬0.51%96.36億 USD0.35%US$140.18-2.73%
iShares Russell 2000 ETFIWM4134.04萬0.06%715.37億 USD0.19%US$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI3355.41萬0.00%6893億 USD0.03%US$340.02-3.52%
Vanguard Extended Market ETFVXF1606.42萬0.02%302億 USD0.05%US$211.44-3.21%
iShares Russell 2000 Value ETFIWN1456.64萬0.11%130.46億 USD0.24%US$198.84-2.08%
iShares Biotechnology ETFIBB1292.56萬0.12%105.27億 USD0.44%US$199.54-2.05%
F/M Emerald Life Sciences Innovation ETFLFSC1164.38萬10.24%1.14億 USD0.79%US$41.575-2.82%
Vanguard Russell 2000 ETFVTWO834.55萬0.05%168億 USD0.06%US$103.76-2.76%
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
iShares Biotechnology ETFIBB
F/M Emerald Life Sciences Innovation ETFLFSC
Vanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。